Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2006

View Archived Issues

Preclinical melanoma, phase I NHL studies of PPI-2458 presented

Gene therapy approach successful for hip prosthesis loosening

BioMarin makes strides in third quarter

Kinases in rheumatology

Combined ramipril and candesartan better than monotherapy in hypertension

Rimonabant reduces liver enzymes in overweight, dyslipidemic patients

Aliskiren reduces renin activity in mono- and combination therapy

Mitsubishi's novel NF-kB inhibitor shows potent antiangiogenic and antitumor activity in vivo

Salvat's SVT-004703 shows antitumor activity by inhibiting tubulin polymerization

MethylGene and EnVivo collaborate with CHDI on Huntington's program

Roxro's intranasal ketorolac provides effective postsurgery pain relief

New therapeutic agents for thrombotic disorders disclosed in recent patent literature

Enrollment suspended in becatecarin phase III program in biliary tract tumors

Novel agents for obesity, lipoprotein disorders, etc. claimed

Novel monoclonal antibodies for renal diseases emerge from Lilly R&D

Clinical advisory meeting for Resverlogix's ApoA-I enhancing technologies

Emerging companies showcased at BIO-Europe 2006: Ablynx

Enrollment opens in pivotal MEND-CABG II study of MC-1

SGN-35 begins phase I study for CD30-positive hematologic malignancies

EVT-201 begins second phase II trial for insomnia

Bavituximab studied with chemotherapy in phase Ib cancer study

Novartis selects preclinical development candidate in Vernalis Hsp90 collaboration

Actelion to acquire CoTherix

Gilead Sciences completes Myogen acquisition

Ferumoxytol meets phase III endpoints in non dialysis-dependent CKD patients

First DC vaccine with clinical activity and therapeutic/chemopreventive potential

NeoRecormon recommended for once weekly use in solid tumor patients in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...